GlassScriptPhysician profile
Philip Lamptey
NPI 1336349315
$934.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $55.86.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $158.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $131.75 | 2019 | |
| Pfizer INC. | $114.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.35 | 2019 | |
| Alexion Pharmaceuticals, INC. | $65.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.94 | 2019 | |
| Merck Sharp & Dohme LLC | $31.08 | 2019 | |
| Novo Nordisk INC | $25.40 | 2019 | |
| Allergan, INC. | $24.08 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.81 | 2019 | |
| Shire North American Group INC | $13.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.42 | 2019 | |
| Amgen INC. | $12.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Lamptey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.